Meaning of DNA detection during the follow-up of HIV-1 infected patients: A brief review

New Microbiologica

Volumn 29, Issue 2, 2006, Pages 81-88

  Re, Maria Carla ^a,b   Vitone, Francesca ^a   Bon, Isabella ^a   Schiavone, Pasqua ^a   Gibellini, Davide ^a  

^a Department of Clinical Experimental Medicine ^*  (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

DNA proviral load; HIV 1; PCR; Viral reservoirs

Indexed keywords

RNA; VIRUS DNA;

FOLLOW UP; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; REVIEW; VIROLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

DNA, VIRAL; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; RNA; VIRAL LOAD; VIRUS INTEGRATION; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745829765     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. BERGER, E.A., MURPHY, P.M., FARBER, J.M. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17, 657-700.
2. BROSTROM, C., VISCO-COMANDINI, U., YUN, Z., SONNERBORG, A. (1999). Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. J Infect Dis 179, 1542-8.
3. BUTLER, S.L., JOHNSON, E.P., BUSHMAN, F.D. (2002). Human Immunodeficiency Virus cDNA Metabolism: Notable Stability of Two-Long Terminal Repeat Circles. J Virol 76, 3739-3747.
4. CHEW, C.B., POTTER, S.J., WANG, B., WANG, Y.M., SHAW, C.O., DWYER, D.E, SAKSENA, N.K. (2005). Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 33, 206-216.
5. CHUN, T.W., ENGEL, D., BERREY, M.M., SHEA, T., COREY, L., FAUCI, A.S. (1998). Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 95, 8869-8873.
6. CLEMENTS, I.E., LI, M., GAMA, L., BULLOCK, B., CARRUTH, L.M., MANKOWSKI, J.L., ZINK, M.C. (2005). The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 11, 180-189.
7. DESIRE, N., DEHEE, A., SCHNEIDER, V., JACOMET, C., GOUJON, C., GIRARD, P.M., ROZENBAUM, W., NICOLAS, J.C. (2001). Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan realtime PCR assay. J Clin Microbiol 39, 1303-1310
8. DIANZANI, F, ANTONELLI, G., AIUTI, F, TURRIZIANI, O., RIVA, E., CAPOBIANCHI, M.R., PANDOLFI, F., D' OFFIZI, G. (2000). The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2. IRHAN Study Group. Antivir Res 45, 95-99.
9. FINZI, D., HERMANKOVA, M., PIERSON, T., CARRUTH, LM, BUCK C, CHAISSON RE, QUINN TC, CHADWICK K, MARGOLICK J, BROOKMEYER R, GALLANT J, MARKOWITZ M, HO DD, RICHMAN DD, SILICIANO RF (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300.
10. FINZI, D., BLANKSON, J., SILICIANO, J.D., MARGOLICK, J.B., CHADWICK, K., PIERSON, T., SMITH, K., LISZIEWICZ, J., LORI, F., FLEXNER, C., QUINN, T.C., CHAISSON, R.E., ROSENBERG, E., WALKER, B., GANGE, S., GALLANT, J., SILICIANO, R.F. (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5, 512-7.
11. FURTADO, M.R., CALLAWAY, D.S., PHAIR, J.P., KUNSTMAN, K.J., STANTON, J.L., MACKEN, C.A., PERELSON, A.S., WOLINSKY, S.M. (1999). Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Eng J Med 340, 1614-1622.
12. GARBUGLIA, A.R., CALCATERRA, S., D'OFFIZI, G., TOPINO, S., NARCISO, P., LILLO, F., GIRARDI, E., CAPOBIANCHI, M.R. (2004). HIV-1 DNA burden dynamics in CD4 T cells and monocytes in patients undergoing a transient therapy interruption. J Med Virol 74, 373-81.
13. GIBELLINI, D., VITONE, F., SCHIAVONE, P., PONTI, C., LA PLACA M., RE MC. (2004). Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J Clin Virol 29, 82-9.
14. GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-1-INFECTED ADULTS AND ADOLESCENTS, http:// www.aidsinfo.nih.govOctober 6, 2005.
15. GUPTA, P., MELLORS, J., KINGSLEY, L., RIDDLER, S., SING, M.K., SCHREIBER, S., CRONIN, M., RINALDO, C.R. (1997). High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and non nucleoside reverse transcriptase inhibitors. J Virol 71, 6271-6275.
16. HAGGERTY, C., PITT, E., SILICIANO R. (2006). The latent reservoir for HIV in resting CD4 cells and other viral reservoirs during chronic infection: insight from treatment and treatment-interruption trials. Curr Op HIV AIDS 1, 62-68.
17. HAMED, K.A., WINTERS, M.A., HOLODINY, M., KATZENSTEIN, D.A., MERIGAN, T.C. (1993). Detection of human immuno-deficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. Journal of Infectious Disease 167, 798-802.
18. HARRINGTON, P.R., HAAS, D.W., RITOLA, K., SWANSTROM, R. (2005). Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 79, 7959-7966.
19. HATZAKIS, A.E., TOULOUMI, G., PANTAZIS, N., ANASTASSOPOULOU, C.G., KATSAROU, O., KARAFOULIDOU, A., GOEDERT, J.J., KOSTRIKIS, L.G. (2004). Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 18, 2261-2267.
20. HAVLIR, D. V., BASSETT, R., LEVITAN, D., GILBERT, P., TEBAS, P., COLLIER, A.C., HIRSCH, M.S., IGNACIO, C., CONDRA, J., GUNTHARD, H.F., RICHMAN, D.D., WONG, J.K. (2001). Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286, 171-179.
21. HERMANKOVA, M., RAY, S.C., RUFF, C., POWELL-DAVIS, M., INGERSOLL, R., D'AQUILA, R.T., QUINN, T.C., SILICIANO, J.D., SILICIANO, R.F., PERSAUD, D. (2001). HIV-1 drug resistance profiles in children and adults with viral load <50 copies/ml receiving combination therapy. JAMA 286, 196-207.
22. HERMANKOVA, M., SILICIANO, J.D., ZHOU, Y., MONIE, D., CHADWICK, K., MARGOLICK, J.B., QUINN, T.C., HO, D., NEUMANN, A.U., PERELSON, A.S., CHEN, W., LEONARD. J.M., MARKOWITZ, M. (2003). Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 77, 7383-92.
23. IMAMICHI, H., CRANDALL, K.A., NATARAJAN, V., JIANG, M.K., DEWAR, R.L., BERG, S., GADDAM, A., BOSCHE, M., METCALF, J.A., DAVEY, R.T. JR, LANE, H.C. (2001). Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 183, 36-50.
24. KOSTRIKIS, L.G., TOULOUMI, G., KARANICOLAS, R., PANTAZIS, N., ANASTASSOPOULOU, C., KARAFOULIDOU, A., GOEDERT, J.J., HATZAKIS, A., MULTICENTER HEMOPHILIA COHORT STUDY GROUP. (2002). Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 76, 10099-10108.
25. KRIEGER, J.N., COOMBS, R.W., COLLIER, A.C., ROSS, S.O., CHALOUPKA, K., CUMMINGS, D.K., MURPHY, V.L., COREY, L. (1991). Recovery of human immunodeficiency virus type 1 from semen: Minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis 163, 386-388.
26. LAFEUILLADE, A., POGGI, C., CHADAPAUD, S., HITTINGER, H., KHIRI, H., HALFON, P. (2001). Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy, HIV Med 2, 189-194.
27. LAMBOTTE, O., CHAIX, M.L., GUBLER, B., NASREDDINE, N., WALLON, C., GOUJARD, C., ROUZIOUX, C., TAOUFIK, Y., DELFRAISSY, J.F. (2004). The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 18, 1147-1158.
28. LIUZZI, G., CHIRIANNI, A., CLEMENTI, M., BAGNARELLI, P., VALENZA, A., CATALDO, P.T., PIAZZA, M. (1996). Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS, 10: F51-F56.
29. MARCELLO, A. 2006. Latency: the hidden HIV-1 challenge Retrovirology 3, 7.
30. MCDERMOTT, J.L., GIRI, A.A., MARTINI, I., BONO, M., GIACOMINI, M., CAMPELLI, A., TAGLIAFERRO, L., CARA, A., VARNIER, O.E. (1999). Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol 37, 2361-2365.
31. MCDERMOTT, J.L., MARTINI, I., FERRARI, D., BERTOLOTTI, F., GIACOMAZZI, C., MURDACA, G., PUPPO, F., INDIVERI, F., VARNIER, O.E. (2005). Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J Clin Microbiol 43, 5272-5274.
32. NGO-GIANG-HUONG, N., DEVEAU, C., DA SILVA, I., PELLEGRIN, I., VENET, A., HARZIC, M. AND FRENCH PRIMO COHORT STUDY GROUP. (2001). Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15, 665-673.
33. NOE, A., PLUM, J., VERHOFSTEDE, C. (2005). The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrobial Chemother 55, 410-412.
34. O'BRIEN, T.R., MCDERMOTT, D.H., IOANNIDIS, J.P., CARRINGTON, M., MURPHY, P.M., HAVLIR, D.V., RICHMAN, D.D. 2000 Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 14, 821-6.
35. PALMISANO, L., GIULIANO, M., NICASTRI, E., PIRILLO, M.F., ANDREOTTI, M., GALLUZZO, C.M., BUCCIARDINI, R., FRAGOLA, V., ANDREONI, M., VELLA, S. (2005). Residual viremia in subjects with chronic HIV infection and viral load <50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 19, 1843-1847.
36. PANTHER, L.A., COOMBS, R.W., ZEH, I.E., COLLIER, A.C., COREY, L. (1998). Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. JAIDS 17, 303-313.
37. PELLEGRIN, I., CAUMONT, A., GARRIGUE, I., MEREL, P., SCHRIVE, M.H., FLEURY, H., DUPON, M., PELLEGRIN, J.L., RAGNAUD, J.M. (2003). Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 187, 38-46.
38. PIERSON, T., MCARTHUR, J., SILICIANO, R.F. (2000). Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18, 665-708.
39. RAMRATNAM, B., MITTLER, J.E., ZHANG, L., BODEN, D., HURLEY, A., FANG, F., MACKEN, C.A., PERELSON, A.S., MARKOWITZ, M., HO, D.D. (2000). The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Med 6: 82-85.
40. RE, M.C., GIBELLINI, D., FURLINI, G., VIGNOLI, M., VITONE, F., BON, I., LA PLACA, M. (2001). Relationships between the presence of anti-Tat antibody, DNA and RNA viral load. New Microbiologica 24, 207-215.
41. RE, M.C., BON, I., MONARI, P., GORINI, R., SCHIAVONE, P., GIBELLINI, D., LA PLACA, M. (2003). Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance. New Microbiologica 26, 405-413.
42. RE, M.C., VITONE, F., SIGHINOLFI, L., SCHIAVONE, P., GHINELLI, F., GIBELLINI, D. (2005). Different patterns of HIV-1 DNA after therapy discontinuation. BMC Infect Dis 12, 69-76.
43. RIVA, E., PISTELLO, M., NARCISO, P., D'OFFIZI, G., ISOLA, P., GALATI, V., TURRIZIANI, O., TOZZI, V., VINCENTI, L., DIANZANI, F., ANTONELLI, G. (2001). Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 17, 1599-604.
44. RIVA, E., ANTONELLI, G., SCAGNOLARI, C., PISTELLO, M., CAPOBIANCHI, M.R., D'ARMINIO MANFORTE, A., PEZZETTI, P., DIANZANI, F. for the I.CO.N.A. Study Group. (2003). Human Immunodeficiency Virus (HIV) DNA load and level of immunosuppression in treatment-naive HIV-1-infectedpatients. J Infect Dis 187, 1826-1828.
45. ROUZIOUX, C., HUBERT, J.B., BURGARD, M., DEVEAU, C., GOUJARD, C., BARY, M., SERENI, D., VIARD, J.P., DELFRAISSY, J.F., MEYER, L. and SEROCO Cohort Study Group. (2005). Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192, 46-55.
46. RUFF, C.T., RAY, S.C., KWON, P., ZINN, R., PENDLETON, A., HUTTON, N., ASHWORTH, R., GANGE, S., QUINN, T.C., SILICIANO, R.F., PERSAUD, D. (2002). Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 76, 9481-92.
47. 3rd, MADY, B., LAI, K.K., MOYLE, G., NELSON, M., GAZZARD, B., SHAUNAK, S., STEVENSON, M. (20009. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nature Med 6, 76-81.
48. SHARKEY, M., TRIQUES, K., KURITZKES, D.R., STEVENSON, M. (2005). In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 79, 5203-5210.
49. SHIRAMIZU, B., GARTNER, S., WILLIAMS, A., SHIKUMA, C., RATTO-KIM, S., WATTERS, M., AGUON, J., VALCOUR, V. (2005). Circulating proviral HIV DNA and HIV-associated dementia. AIDS, 19: 45-52.
50. SILICIANO, J.D., KAJDAS, J., FINZI, D., QUINN, T.C., CHADWICK, K., MARGOLICK, J.B., KOVACS, C., GANGE, S.J., SILICIANO, R.F. (2003). Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine, 9, 727-728.
51. SILICIANO, R.F. (2003). alysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 7, 7383-7392.
52. STRAIN, M.C., LITTLE, S.J., DAAR, E.S., HAVLIR, D.V., GUNTHARD, H.F., LAM, R.Y., DALY, O.A., NGUYEN, J., IGNACIO, C.C., SPINA, C.A., RICHMAN, D.D., WONG, J.K. (2005). Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191, 1410-1418.
53. TIERNEY, C., LATHEY, J.L., CHRISTOPHERSON, C., BETTENDORF, D.M., D'AQUILA, R.T., HAMMER, S.M., KATZENSTEIN, D.A. (2003). Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. AIDS Clinical Trial Group. J Infect Dis 187, 144-148.
54. VALENTIN, A., ROSATI, M., PATENAUDE, D.J., HATZAKIS, A., KOSTRIKIS, L.G., LAZANAS, M., WYVILL, K.M., YARCHOAN, R., PAVLAKIS, G.N. (2002). Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 7015-7020.
55. VERNAZZA, P.L., GILLIAM, B.L., FLEPP, M., DYER, J.R., FRANK, A.C., FISCUS, S.A., COHEN, M.S., ERON, J.J. (1997). Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 11, 1249-1254.
56. VITONE, F., GIBELLINI, D., SCHIAVONE, P., RE, M.C. (2005). Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J Clin Virol 33, 194-200.
57. WONG, J.K., HEZAREH, M., GUNTHARD, H.F., HAVLIR, D.V., IGNACIO, C.C., SPINA, C.A., RICHMAN, D.D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295.
58. ZHANG, L., RAMRATNAM, B., TENNER-RACZ, K., HE, Y., VESANEN, M., LEWIN, S., TALAL, A., RACZ, P., PERELSON, A.S., KORBER, B.T., MARKOWITZ, M., Ho, D.D. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340, 1605-1613.